JP7366996B2 - 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤 - Google Patents

抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤 Download PDF

Info

Publication number
JP7366996B2
JP7366996B2 JP2021506031A JP2021506031A JP7366996B2 JP 7366996 B2 JP7366996 B2 JP 7366996B2 JP 2021506031 A JP2021506031 A JP 2021506031A JP 2021506031 A JP2021506031 A JP 2021506031A JP 7366996 B2 JP7366996 B2 JP 7366996B2
Authority
JP
Japan
Prior art keywords
optionally substituted
mmol
bromo
reduced pressure
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021506031A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019201283A5 (enExample
JP2021522316A (ja
Inventor
ワン，ヤオデ
フー，ジアンミン
スン，ユエ
ウー，グオシェン
ルー，アイジュン
ジャン，シュアン
グッドナウ，ロバート
ギルマー，トナ
カスタン，マイケル
キルシュ，デビッド
Original Assignee
エクスラッド セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクスラッド セラピューティクス，インコーポレーテッド filed Critical エクスラッド セラピューティクス，インコーポレーテッド
Priority claimed from PCT/CN2019/083104 external-priority patent/WO2019201283A1/en
Publication of JP2021522316A publication Critical patent/JP2021522316A/ja
Publication of JPWO2019201283A5 publication Critical patent/JPWO2019201283A5/ja
Application granted granted Critical
Publication of JP7366996B2 publication Critical patent/JP7366996B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021506031A 2018-04-20 2019-04-17 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤 Active JP7366996B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810359447.6 2018-04-20
CN201810359447.6A CN110386932A (zh) 2018-04-20 2018-04-20 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US201862665296P 2018-05-01 2018-05-01
US62/665,296 2018-05-01
PCT/CN2019/083104 WO2019201283A1 (en) 2018-04-20 2019-04-17 Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Publications (3)

Publication Number Publication Date
JP2021522316A JP2021522316A (ja) 2021-08-30
JPWO2019201283A5 JPWO2019201283A5 (enExample) 2022-04-22
JP7366996B2 true JP7366996B2 (ja) 2023-10-23

Family

ID=68283636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506031A Active JP7366996B2 (ja) 2018-04-20 2019-04-17 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤

Country Status (10)

Country Link
US (1) US12187742B2 (enExample)
EP (2) EP4327877A3 (enExample)
JP (1) JP7366996B2 (enExample)
KR (1) KR20210027251A (enExample)
CN (2) CN110386932A (enExample)
BR (1) BR112020021323A2 (enExample)
CA (1) CA3096732A1 (enExample)
MA (1) MA52364A (enExample)
MX (1) MX2020010942A (enExample)
SG (1) SG11202010212RA (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN119684291A (zh) * 2019-07-30 2025-03-25 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN114746421A (zh) * 2019-11-19 2022-07-12 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
EP4063371A1 (en) * 2019-11-22 2022-09-28 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors
WO2021136462A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN114634521A (zh) * 2020-12-15 2022-06-17 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CN121152622A (zh) * 2023-03-06 2025-12-16 艾科思莱德控股开曼有限公司 治疗癌症的方法
WO2025247391A1 (en) * 2024-05-31 2025-12-04 Hutchmed Limited Novel pi3k and/or pikk inhibitors, antibody-drug conjugates comprising the same and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
CN103880844A (zh) 2014-04-09 2014-06-25 彭正中 一种喹啉酮类新化合物及其制备方法与用途
JP2015521600A (ja) 2012-06-13 2015-07-30 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤としての置換三環式化合物
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
NZ573049A (en) 2006-06-01 2010-08-27 Sanofi Aventis Spirocyclic nitriles as protease inhibitors
KR101504669B1 (ko) 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
AR089929A1 (es) 2012-02-10 2014-10-01 Actelion Pharmaceuticals Ltd Proceso para manufacturar un derivado de naftiridina
CN103936762B (zh) * 2013-01-17 2016-02-24 上海汇伦生命科技有限公司 吗啉并喹啉类化合物，其制备方法和用途
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
CN105461712B (zh) * 2014-06-17 2019-01-29 上海嘉坦医药科技有限公司 作为mTOR/PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
KR102495840B1 (ko) * 2014-06-17 2023-02-03 치아타이 티안큉 파마수티컬 그룹 주식회사 PI3K 억제제로 사용되는 피리디노[1,2-a]피리미돈 유사체
RU2658912C1 (ru) * 2014-06-17 2018-06-26 Шанхай Цзя Тань Фарматек Ко. Лтд. АНАЛОГ ПИРИДИНО[1,2-А]ПИРИМИДОНА, ИСПОЛЬЗУЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА mTOR/PI3K
CN105461711B (zh) * 2014-06-17 2018-11-06 正大天晴药业集团股份有限公司 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
EP3194369A4 (en) 2014-09-17 2018-02-28 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
HUE054745T2 (hu) 2015-04-02 2021-09-28 Merck Patent Gmbh Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3405465B1 (en) 2016-01-20 2021-10-13 Biogen MA Inc. Irak4 inhibiting agents
WO2017162611A1 (en) * 2016-03-21 2017-09-28 Astrazeneca Ab Quinoline-3-carboxamide compounds and their use in treating cancer
TWI696615B (zh) 2016-05-05 2020-06-21 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN112771045B (zh) * 2018-09-30 2022-04-19 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN119684291A (zh) 2019-07-30 2025-03-25 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155527A2 (en) 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
JP2014504286A (ja) 2010-12-06 2014-02-20 ピラマル エンタープライジーズ リミテッド 置換イミダゾキノリン誘導体
JP2015521600A (ja) 2012-06-13 2015-07-30 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ阻害剤としての置換三環式化合物
CN103880844A (zh) 2014-04-09 2014-06-25 彭正中 一种喹啉酮类新化合物及其制备方法与用途
WO2016186453A1 (en) 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors

Also Published As

Publication number Publication date
AU2019254980A1 (en) 2020-12-03
EP4327877A3 (en) 2024-04-24
US20220315606A1 (en) 2022-10-06
EP4327877A2 (en) 2024-02-28
US12187742B2 (en) 2025-01-07
CA3096732A1 (en) 2019-10-24
CN112469720A (zh) 2021-03-09
JP2021522316A (ja) 2021-08-30
CN112469720B (zh) 2024-03-29
CN110386932A (zh) 2019-10-29
MA52364A (fr) 2021-03-03
BR112020021323A2 (pt) 2021-01-19
SG11202010212RA (en) 2020-11-27
MX2020010942A (es) 2021-01-15
EP3784671A1 (en) 2021-03-03
KR20210027251A (ko) 2021-03-10
EP3784671B1 (en) 2023-10-11
EP3784671A4 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
JP7366996B2 (ja) 抗腫瘍療法で使用するためのデュアルａｔｍ及びｄｎａ－ｐｋ阻害剤
WO2019201283A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JP7392164B2 (ja) ヘテロアリール誘導体、その製造方法およびその使用
JP6380862B2 (ja) 複数種類のキナーゼの阻害剤としての縮合三環式アミド系化合物
JP6208223B2 (ja) 新規化合物
JP7595959B2 (ja) 抗腫瘍療法において使用するための二重ａｔｍ及びｄｎａ－ｐｋ阻害剤
JP2011137018A (ja) 置換キノリン−４−イルアミン類縁体
EA030141B1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
CN103596926A (zh) 作为raf激酶抑制剂的稠合三环化合物
PT2820008T (pt) Amidas amido-espirocíclicas e derivados de sulfonamidas
BR112017026191B1 (pt) Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos
WO2014079364A1 (zh) 咪唑酮类衍生物、其药物组合物和用途
TW202421130A (zh) 作為pi3k抑制劑的異喹啉酮
JP2023538096A (ja) Ｒｅｔキナーゼ阻害剤としてのヘテロ芳香族環化合物及びその製造と使用
WO2023036156A1 (zh) Dna-pk选择性抑制剂及其制备方法和用途
TW202220987A (zh) 經取代雜環化合物及其治療用途
JP2008515988A (ja) 置換ビアリールキノリン−４−イルアミン類縁体
KR20250029184A (ko) Wee1 분해 화합물 및 그의 용도
CN104822658B (zh) 作为多种激酶抑制剂的稠合三环酰胺类化合物
EP3012259B1 (en) Five-membered heterocyclic pyridine compounds and preparation method and use thereof
JP2024506518A (ja) アザヘテロアリール化合物、その調製方法及び使用
TWI640518B (zh) 作爲ｒａｆ激酶抑制劑的稠合三環化合物
CN105348299B (zh) 作为raf激酶抑制剂的稠合三环化合物
HK40047614B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HK40047614A (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201216

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231011

R150 Certificate of patent or registration of utility model

Ref document number: 7366996

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113